Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests

Published June 27, 2026 · Category: Finance

Overview

Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026, as disclosed in a SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($40.24); post-transaction value based on June 18, 2026 market close.

Details

Vericel Corporation operates as a commercial-stage biopharmaceutical company specializing in advanced cell therapies for sports medicine and burn care. With a focused product portfolio and established distribution in the U.S. hospital and specialty clinic markets, the company leverages proprietary technologies to address unmet medical needs. Its strategy centers on expanding the adoption of its FDA-approved therapies and advancing new indications to strengthen its competitive position in regenerative medicine.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• Vesta Director Sells $203,000 in Stock While Shares Gain 25% in a Year
• Where Will Solana Be in 3 Years?
• This Vanguard Index Fund Could Be the Best Financial Decision You Ever Make